Skip to Main Content

658

Views

0

CrossRef citations to date

0

Altmetric

Research Article

Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials

Jennifer Sounga Southern California Dermatology, Inc, Santa Ana, CA, USACorrespondence[email protected]
View further author information

,

Sonja Ständerb University Hospital Westphalian Wilhems University, Munster, GermanyView further author information

,

Jan Gutermuthc Department of Dermatology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Jette, BelgiumView further author information

,

Ignasi Pau-Charlesd Almirall, Barcelona, SpainView further author information

,

Zach Dawsone Eli Lilly and Company, Indianapolis, IN, USAView further author information

,

Fan Emily Yange Eli Lilly and Company, Indianapolis, IN, USAView further author information

,

Luna Sune Eli Lilly and Company, Indianapolis, IN, USAView further author information

,

Evangeline Piercee Eli Lilly and Company, Indianapolis, IN, USAView further author information

,

Hany Elmaraghye Eli Lilly and Company, Indianapolis, IN, USAView further author information

&

Linda Stein-Goldf Clinic for Dermatology, Henry Ford Health System, Detroit, MI, USAView further author information